| Name | Title | Contact Details |
|---|
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
Trenton Medical Center Inc is a Trenton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Advanced Products Inc is a Conway, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sequel Systems is a Melville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Biosign Technologies Inc. engages in the development, manufacture, and sale of medical devices and information systems. The company provides cloud based systems for non-invasive monitoring of common health risks associated with blood pressure, life style, and medication. Its analysis and reporting tools give patients and their healthcare team access to real-time health information for treatment planning, evaluation, and management. The company offers UFIT, an automated wrist sphygmography system with computer controls that measures various signs, including blood pressure, mean arterial pressure, pulse rate, and pulse rate variability from a single digital signal acquired passively with an inflatable cuff at the wrist. It also provides Healthanywhere, a software-based, remote patient monitoring application that runs on Windows PC and Blackberry platforms. Healthanywhere solution provides for the continuum of care from wellness promotion to self-managed care, including monitoring of chronic diseases, such as congestive heart failure, hypertension, diabetes, asthma, and obesity. Biosign Technologies Inc. was incorporated in 2004 and is headquartered in Thornhill, Canada.